|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Carey LA, Perou CM, Livasy CA, Dressler
LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S,
et al: Race, breast cancer subtypes, and survival in the Carolina
Breast Cancer Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sorlie T, Tibshirani R, Parker J, Hastie
T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et
al: Repeated observation of breast tumor subtypes in independent
gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cascione L, Gasparini P, Lovat F, Carasi
S, Pulvirenti A, Ferro A, Alder H, He G, Vecchione A, Croce CM, et
al: Integrated microRNA and mRNA signatures associated with
survival in triple negative breast cancer. PLoS One. 8:e559102013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gasparini P, Cascione L, Fassan M, Lovat
F, Guler G, Balci S, Irkkan C, Morrison C, Croce CM, Shapiro CL, et
al: microRNA expression profiling identifies a four microRNA
signature as a novel diagnostic and prognostic biomarker in triple
negative breast cancers. Oncotarget. 5:1174–1184. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kleivi Sahlberg K, Bottai G, Naume B,
Burwinkel B, Calin GA, Børresen-Dale AL and Santarpia L: A serum
microRNA signature predicts tumor relapse and survival in
triple-negative breast cancer patients. Clin Cancer Res.
21:1207–1214. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Robinson MD, McCarthy DJ and Smyth GK:
edgeR: A BioconductoR package for differential expression analysis
of digital gene expression data. Bioinformatics. 26:139–140. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dawson SJ, Provenzano E and Caldas C:
Triple negative breast cancers: Clinical and prognostic
implications. Eur J Cancer. 45 (Suppl 1):S27–S40. 2009. View Article : Google Scholar
|
|
12
|
Santarpia L, Qi Y, Stemke-Hale K, Wang B,
Young EJ, Booser DJ, Holmes FA, O'Shaughnessy J, Hellerstedt B,
Pippen J, et al: Mutation profiling identifies numerous rare drug
targets and distinct mutation patterns in different clinical
subtypes of breast cancers. Breast Cancer Res Treat. 134:333–343.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang L, Huang J, Yang N, Greshock J,
Megraw MS, Giannakakis A, Liang S, Naylor TL, Barchetti A, Ward MR,
et al: microRNAs exhibit high frequency genomic alterations in
human cancer. Proc Natl Acad Sci USA. 103:9136–9141. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tan Y, Zhang B, Wu T, Skogerbø G, Zhu X,
Guo X, He S and Chen R: Transcriptional inhibiton of Hoxd4
expression by miRNA-10a in human breast cancer cells. BMC Mol Biol.
10:122009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yan Y, Wang Q, Yan XL, Zhang Y, Li W, Tang
F, Li X and Yang P: miR-10a controls glioma migration and invasion
through regulating epithelial-mesenchymal transition via
EphA8. FEBS Lett. 589:756–765. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Markou A, Sourvinou I, Vorkas PA, Yousef
GM and Lianidou E: Clinical evaluation of microRNA expression
profiling in non small cell lung cancer. Lung Cancer. 81:388–396.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gaur A, Jewell DA, Liang Y, Ridzon D,
Moore JH, Chen C, Ambros VR and Israel MA: Characterization of
microRNA expression levels and their biological correlates in human
cancer cell lines. Cancer Res. 67:2456–2468. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ma L: Role of miR-10b in breast cancer
metastasis. Breast Cancer Res. 12:2102010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Han J, Kim D and Morris KV:
Promoter-associated RNA is required for RNA-directed
transcriptional gene silencing in human cells. Proc Natl Acad Sci
USA. 104:12422–12427. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu WH, Yeh SH, Lu CC, Yu SL, Chen HY, Lin
CY, Chen DS and Chen PJ: MicroRNA-18a prevents estrogen
receptor-alpha expression, promoting proliferation of
hepatocellular carcinoma cells. Gastroenterology. 136:683–693.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Calvano Filho CM, Calvano-Mendes DC,
Carvalho KC, Maciel GA, Ricci MD, Torres AP, Filassi JR and Baracat
EC: Triple-negative and luminal A breast tumors: Differential
expression of miR-18a-5p, miR-17-5p, and miR-20a-5p. Tumour Biol.
35:7733–7741. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fan YX, Dai YZ, Wang XL, Ren YQ, Han JJ
and Zhang H: MiR-18a upregulation enhances autophagy in triple
negative cancer cells via inhibiting mTOR signaling pathway. Eur
Rev Med Pharmacol Sci. 20:2194–2200. 2016.PubMed/NCBI
|
|
23
|
Sha LY, Zhang Y, Wang W, Sui X, Liu SK,
Wang T and Zhang H: MiR-18a upregulation decreases dicer expression
and confers paclitaxel resistance in triple negative breast cancer.
Eur Rev Med Pharmacol Sci. 20:2201–2208. 2016.PubMed/NCBI
|
|
24
|
Dai X, Chen A and Bai Z: Integrative
investigation on breast cancer in ER, PR and HER2-defined subgroups
using mRNA and miRNA expression profiling. Sci Rep. 4:65662014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Uva P, Cossu-Rocca P, Loi F, Pira G,
Murgia L, Orrù S, Floris M, Muroni MR, Sanges F, Carru C, et al:
miRNA-135b contributes to triple negative breast cancer molecular
heterogeneity: Different expression profile in basal-like versus
non-basal-like phenotypes. Int J Med Sci. 15:536–548. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Paszek S, Gablo N, Barnas E, Szybka M,
Morawiec J, Kołacińska A and Zawlik I: Dysregulation of microRNAs
in triple-negative breast cancer. Ginekol Pol. 88:530–536. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Buffa FM, Camps C, Winchester L, Snell CE,
Gee HE, Sheldon H, Taylor M, Harris AL and Ragoussis J:
microRNA-associated progression pathways and potential therapeutic
targets identified by integrated mRNA and microRNA expression
profiling in breast cancer. Cancer Res. 71:5635–5645. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pan HW, Li SC and Tsai KW: MicroRNA
dysregulation in gastric cancer. Curr Pharm Des. 19:1273–1284.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tatarano S, Chiyomaru T, Kawakami K,
Enokida H, Yoshino H, Hidaka H, Yamasaki T, Kawahara K, Nishiyama
K, Seki N, et al: miR-218 on the genomic loss region of chromosome
4p15.31 functions as a tumor suppressor in bladder cancer. Int J
Oncol. 39:13–21. 2011.PubMed/NCBI
|
|
30
|
Kolacinska A, Morawiec J, Fendler W,
Malachowska B, Morawiec Z, Szemraj J, Pawlowska Z, Chowdhury D,
Choi YE, Kubiak R, et al: Association of microRNAs and pathologic
response to preoperative chemotherapy in triple negative breast
cancer: Preliminary report. Mol Biol Rep. 41:2851–2857. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yin C, Mou Q, Pan X, Zhang G, Li H and Sun
Y: MiR-577 suppresses epithelial-mesenchymal transition and
metastasis of breast cancer by targeting Rab25. Thorac Cancer.
9:472–479. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao G, Zhang JG, Liu Y, Qin Q, Wang B,
Tian K, Liu L, Li X, Niu Y, Deng SC, et al: miR-148b functions as a
tumor suppressor in pancreatic cancer by targeting AMPKalpha1. Mol
Cancer Ther. 12:83–93. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang JS, Li BJ, Lu HW, Chen Y, Lu C, Zhu
RX, Liu SH, Yi QT, Li J and Song CH: Serum miR-152, miR-148a,
miR-148b, and miR-21 as novel biomarkers in non-small cell lung
cancer screening. Tumour Biol. 36:3035–3042. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang JG, Shi Y, Hong DF, Song M, Huang D,
Wang CY and Zhao G: MiR-148b suppresses cell proliferation and
invasion in hepatocellular carcinoma by targeting WNT1/β-catenin
pathway. Sci Rep. 5:80872015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ziari K, Zarea M, Gity M, Fayyaz AF,
Yahaghi E, Darian EK and Hashemian AM: Downregulation of miR-148b
as biomarker for early detection of hepatocellular carcinoma and
may serve as a prognostic marker. Tumour Biol. 37:5765–5768. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Furuta M, Kozaki KI, Tanaka S, Arii S,
Imoto I and Inazawa J: miR-124 and miR-203 are epigenetically
silenced tumor-suppressive microRNAs in hepatocellular carcinoma.
Carcinogenesis. 31:766–776. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Saini S, Majid S, Yamamura S, Tabatabai L,
Suh SO, Shahryari V, Chen Y, Deng G, Tanaka Y and Dahiya R:
Regulatory role of mir-203 in prostate cancer progression and
metastasis. Clin Cancer Res. 17:5287–5298. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang Z, Zhang B, Li W, Fu L, Fu L, Zhu Z
and Dong JT: Epigenetic silencing of miR-203 upregulates
SNAI2 and contributes to the invasiveness of malignant
breast cancer cells. Genes Cancer. 2:782–791. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chiang Y, Song Y, Wang Z, Chen Y, Yue Z,
Xu H, Xing C and Liu Z: Aberrant expression of miR-203 and its
clinical significance in gastric and colorectal cancers. J
Gastrointest Surg. 15:63–70. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Greither T, Grochola LF, Udelnow A,
Lautenschlager C, Wurl P and Taubert H: Elevated expression of
microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated
with poorer survival. Int J Cancer. 126:73–80. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hezova R, Kovarikova A, Srovnal J,
Zemanova M, Harustiak T, Ehrmann J, Hajduch M, Svoboda M, Sachlova
M and Slaby O: Diagnostic and prognostic potential of miR-21,
miR-29c, miR-148 and miR-203 in adenocarcinoma and squamous cell
carcinoma of esophagus. Diagn Pathol. 10:422015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Frisch SM and Francis H: Disruption of
epithelial cell-matrix interactions induces apoptosis. J Cell Biol.
124:619–626. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Streuli CH and Gilmore AP:
Adhesion-mediated signaling in the regulation of mammary epithelial
cell survival. J Mammary Gland Biol Neoplasia. 4:183–191. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Park SH, Riley P IV and Frisch SM:
Regulation of anoikis by deleted in breast cancer-1 (DBC1) through
NF-κB. Apoptosis. 18:949–962. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Garofalo M, Leva GD and Croce CM:
MicroRNAs as anti-cancer therapy. Curr Pharm Des. 20:5328–5335.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
DiGiovanna MP, Stern DF, Edgerton SM,
Whalen SG, Moore D II and Thor AD: Relationship of epidermal growth
factor receptor expression to ErbB-2 signaling activity and
prognosis in breast cancer patients. J Clin Oncol. 23:1152–1160.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Vonderhaar BK: Prolactin involvement in
breast cancer. Endocr Relat Cancer. 6:389–404. 1999. View Article : Google Scholar : PubMed/NCBI
|
